Takeda Pharmaceutical Introduces New Measles-Rubella Vaccine.Tokyo, Japan, Jan 30, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Takeda Pharmaceutical announced on January 30 that it has launched Takeda, its proprietary measles-rubella (MR) vaccine. This freeze-dried, live attenuated Attenuated Alive but weakened; an attenuated microorganism can no longer produce disease. Mentioned in: Tuberculin Skin Test attenuated having undergone a process of attenuation. MR vaccine, which combines the company's existing measles measles or rubeola (r  bē`ələ), highly contagious disease of young children, caused by a filterable virus and spread by droplet spray from the nose, mouth, vaccine and rubella vaccine rubella vaccine See MMR vaccine. , is in line with the revision of the Preventive Vaccination Law scheduled to go into effect on April 1. Until then the new vaccine is available for voluntary vaccination. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion